Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma

被引：24
|
作者：
Jiang, Lei [1 ]
Li, Luan [2 ]
Liu, Yongzhuang [3 ]
Lu, Ligong [1 ]
Zhan, Meixiao [1 ]
Yuan, Shengtao [3 ]
Liu, Yanyan [1 ]
机构：
[1] Jinan Univ, Zhuhai Peoples Hosp, Guangdong Prov Key Lab Tumor Intervent Diag & Trea, Zhuhai Hosp, Zhuhai, Guangdong, Peoples R China
[2] Nanjing Med Univ, Jiangsu Canc Hosp, Jiangsu Inst Canc Res, Affiliated Canc Hosp, Nanjing, Jiangsu, Peoples R China
[3] China Pharmaceut Univ, Jiangsu Key Lab Drug Screening, Nanjing, Jiangsu, Peoples R China
来源：
FRONTIERS IN PHARMACOLOGY | 2023年 / 14卷
基金：
中国国家自然科学基金;
关键词：
hepatocellular carcinom; drug resistance; sorafenib; lenvatinib; regorafenib; cabozantinib; TIVANTINIB ARQ 197; OVERCOMES SORAFENIB RESISTANCE; CANCER STEM-CELL; ACQUIRED-RESISTANCE; 2ND-LINE THERAPY; C-MET; LENVATINIB; ANGIOGENESIS; ACTIVATION; PATHWAY;
D O I：
10.3389/fphar.2023.1097277
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer, and it usually occurs following chronic liver disease. Although some progress has been made in the treatment of HCC, the prognosis of patients with advanced HCC is not optimistic, mainly because of the inevitable development of drug resistance. Therefore, multi-target kinase inhibitors for the treatment of HCC, such as sorafenib, lenvatinib, cabozantinib, and regorafenib, produce small clinical benefits for patients with HCC. It is necessary to study the mechanism of kinase inhibitor resistance and explore possible solutions to overcome this resistance to improve clinical benefits. In this study, we reviewed the mechanisms of resistance to multi-target kinase inhibitors in HCC and discussed strategies that can be used to improve treatment outcomes.
引用
收藏
页数：11
相关论文
共 50 条
  • [21] Cancer Metabolism as a Mechanism of Treatment Resistance and Potential Therapeutic Target in Hepatocellular Carcinoma
    Lee, Misu
    Ko, Haeyong
    Yun, Mijin
    YONSEI MEDICAL JOURNAL, 2018, 59 (10) : 1143 - 1149
  • [22] TGF-β activated EGFr as a bypass mechanism for the acquired resistance of MET inhibitors in hepatocellular carcinoma
    Rountree, Carl B.
    Ding, Wei
    Dang, Hien
    Steinway, Steve
    CANCER RESEARCH, 2012, 72
  • [23] Molecular Mechanism of Protein Kinase A in Fibrolamellar Hepatocellular Carcinoma
    Faradonbeh, Mahsa Shirani
    FASEB JOURNAL, 2019, 33
  • [24] Histone deacetylase inhibitors for treatment of hepatocellular carcinoma
    Coradini, D
    Speranza, A
    ACTA PHARMACOLOGICA SINICA, 2005, 26 (09) : 1025 - 1033
  • [25] Histone deacetylase inhibitors for treatment of hepatocellular carcinoma
    Danila CORADINI
    Annalisa SPERANZA
    ActaPharmacologicaSinica, 2005, (09) : 1025 - 1033
  • [26] Immune checkpoint inhibitors in the treatment of hepatocellular carcinoma
    Akbulut, Zeynep
    Aru, Basak
    Aydin, Furkan
    Demirel, Gulderen Yanikkaya
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [27] The role of mTOR inhibitors in the treatment of hepatocellular carcinoma
    Huang, Yi-Hsiang
    Lin, Han-Chieh
    LIVER INTERNATIONAL, 2013, 33 (08) : 1133 - 1134
  • [28] Histone deacetylase inhibitors for treatment of hepatocellular carcinoma
    Danila Coradini
    Annalisa Speranza
    Acta Pharmacologica Sinica, 2005, 26 : 1025 - 1033
  • [29] Is There Still a Place for Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma at the Time of Immunotherapies? A Focus on Lenvatinib
    Decraecker, Marie
    Toulouse, Caroline
    Blanc, Jean-Frederic
    CANCERS, 2021, 13 (24)
  • [30] The Combining of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Stage Hepatocellular Carcinoma
    Lee, Shou-Wu
    Yang, Sheng-Shun
    Lien, Han-Chung
    Peng, Yen-Chun
    Tung, Chun-Fang
    Lee, Teng-Yu
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (16)
12345